Your browser doesn't support javascript.
loading
Usefulness of Global Longitudinal Strain-Guided Management in Preventing Human Epidermal Growth Factor Receptor 2 (HER2) Inhibitor-Induced Myocardial Damage.
Yamada, Kenta; Tamura, Yudai; Taniguchi, Hirohisa; Furukawa, Asuka; Iwasawa, Jin; Yada, Hirotaka; Kawamura, Akio; Tamura, Yuichi.
Afiliação
  • Yamada K; Cardiovascular Center, International University of Health and Welfare Mita Hospital Tokyo Japan.
  • Tamura Y; Department of Cardiology, International University of Health and Welfare, School of Medicine Narita Japan.
  • Taniguchi H; Cardiovascular Center, International University of Health and Welfare Mita Hospital Tokyo Japan.
  • Furukawa A; Department of Cardiology, International University of Health and Welfare, School of Medicine Narita Japan.
  • Iwasawa J; Cardiovascular Center, International University of Health and Welfare Mita Hospital Tokyo Japan.
  • Yada H; Cardiovascular Center, International University of Health and Welfare Mita Hospital Tokyo Japan.
  • Kawamura A; Cardiovascular Center, International University of Health and Welfare Mita Hospital Tokyo Japan.
  • Tamura Y; Cardiovascular Center, International University of Health and Welfare Mita Hospital Tokyo Japan.
Circ Rep ; 4(11): 526-532, 2022 Nov 10.
Article em En | MEDLINE | ID: mdl-36408358
ABSTRACT

Background:

Trastuzumab, an anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody, is a specific first-line treatment for patients with HER2-positive cancers. Cardiac dysfunction is among the most problematic adverse events associated with trastuzumab. Although regular echocardiographic screening is recommended for early detection of cardiac damage, few reports have investigated the validity of echocardiographic screening in chemotherapy. Therefore, the aim of this study was to determine whether a GLS-guided management approach could reduce cardiotoxicity and discontinuation of trastuzumab chemotherapy. Methods and 

Results:

To evaluate the usefulness of global longitudinal strain (GLS)-guided cardioprotective interventions, we retrospectively analyzed 67 patients treated with trastuzumab who underwent structured echocardiographic assessments before and after 1, 3, and 6 courses of trastuzumab administration. If a >15% relative decrease in GLS was identified, cardioprotective agents were administered. Thirty (44.8%) patients had breast cancer; the remaining patients had salivary gland cancer. The median observation period for the intervention group was 304 days from the initial evaluation. Nineteen (28.4%) patients exhibited a >15% relative decrease in GLS, and consequently received cardioprotective agents. The incidence of trastuzumab discontinuation for cardiogenic reasons was significantly lower among patients receiving GLS-guided interventions than among those not receiving the intervention (2.4% vs. 24.0%; P=0.009). The incidence of a subsequent decline in left ventricular ejection fraction was lower among patients receiving the intervention than among those not receiving the intervention (4.8% vs. 24.0%; P=0.04).

Conclusions:

GLS-guided cardioprotective intervention significantly decreased the incidence of trastuzumab discontinuation.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies / Screening_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies / Screening_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article